Virometix AG Secures $15 Million Financing to Advance Vaccine Development
Virometix AG, a Switzerland-based biotechnology firm, has successfully completed a financing round, raising $15 million from existing shareholders. This funding will primarily support the ongoing clinical development of V-212, the…